SonoThera Presents New Data at ASH 2025 Demonstrating Durable Factor VIII Expression Using Ultrasound Mediated Gene Delivery in Treating Hemophilia A
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9th in Orlando, Florida.
SonoThera Presents New Data at ASN Kidney Week 2025 Demonstrating Full-Length Col4a5 Gene Expression Using Ultrasound Mediated Gene Delivery in Treating X-Linked Alport Syndrome
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the American Society of Nephrology’s annual meeting being held November 5-9 in Houston, Texas.
SonoThera™ Presents New Data at ESGCT 2025 Demonstrating Expression of Full-Length Human Dystrophin Using Targeted, Ultrasound-Mediated Delivery to Treat Duchenne Muscular Dystrophy
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 32nd congress of the European Society of Gene and Cell Therapy being held October 7-10 in Seville, Spain.
SonoThera™ to Present New Data at ASGCT 2025 Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery in Treating Duchenne Muscular Dystrophy and Hemophilia A
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through developing the next generation of genetic medicines, today announced it will present new data at the 28th annual American Society of Gene and Cell Therapy (ASGCT) meeting being held May 13-17th in New Orleans, Louisiana.
SonoThera Presents New Data at the 2025 MDA Conference Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery (UMD) in Treating Duchenne Muscular Dystrophy
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through developing the next generation of genetic medicines, today announced it will present new data at the annual Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 16-19th in Dallas, Texas.
SonoThera to Present Preclinical Data on Ultrasound-Mediated Gene Delivery Platform to the Heart at the American Heart Association (AHA) Scientific Sessions 2024
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced it will deliver late-breaking data at the American Heart Association (AHA) Scientific Sessions being held November 15 –18, 2024 in Chicago, Illinois.
SonoThera to Present at ASN Kidney Week 2024 Demonstrating the Potential of Novel Nonviral Ultrasound-Mediated Gene Therapy Delivery Platform
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced that it will deliver three presentations at the American Society of Nephrology Kidney Week 2024 annual meeting taking place in San Diego, California, October 23-27, 2024.
SonoThera™ Receives Exclusive Licensing of GE HealthCare’s Optison® and Sonazoid® Microbubble Products for use with its Ultrasound-guided Gene Therapy Platform
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced it has received exclusive, global, commercial licensing rights from GE HealthCare (Nasdaq:GEHC) for use of Optison® and Sonazoid® microbubble products. The products are being used in the development of SonoThera’s novel, ultrasound-guided nonviral gene therapy platform.
SonoThera™ Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced completion of its $60.75M Series A financing round. The financing will support the continued development of SonoThera’s ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.
